- Home
- REVB vs TCRT Comparison
REVB vs TCRT Comparison
Compare REVB & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- TCRT
- Stock Information
- Founded
- REVB 2020
- TCRT 1998
- Country
- REVB United States
- TCRT United States
- Employees
- REVB N/A
- TCRT N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- TCRT Health Care
- Exchange
- REVB Nasdaq
- TCRT Nasdaq
- Market Cap
- REVB 3.8M
- TCRT 3.8M
- IPO Year
- REVB N/A
- TCRT N/A
- Fundamental
- Price
- REVB $2.88
- TCRT $2.81
- Analyst Decision
- REVB
- TCRT
- Analyst Count
- REVB 0
- TCRT 0
- Target Price
- REVB N/A
- TCRT N/A
- AVG Volume (30 Days)
- REVB 269.2K
- TCRT 59.9K
- Earning Date
- REVB 08-08-2025
- TCRT 08-13-2025
- Dividend Yield
- REVB N/A
- TCRT N/A
- EPS Growth
- REVB N/A
- TCRT N/A
- EPS
- REVB N/A
- TCRT N/A
- Revenue
- REVB N/A
- TCRT $11,000.00
- Revenue This Year
- REVB N/A
- TCRT $5,680,500.00
- Revenue Next Year
- REVB N/A
- TCRT N/A
- P/E Ratio
- REVB N/A
- TCRT N/A
- Revenue Growth
- REVB N/A
- TCRT 83.33
- 52 Week Low
- REVB $2.11
- TCRT $1.31
- 52 Week High
- REVB $168.00
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- REVB 44.79
- TCRT 32.13
- Support Level
- REVB $2.97
- TCRT $2.82
- Resistance Level
- REVB $3.18
- TCRT $3.22
- Average True Range (ATR)
- REVB 0.23
- TCRT 0.50
- MACD
- REVB 0.13
- TCRT -0.22
- Stochastic Oscillator
- REVB 60.37
- TCRT 8.32
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.